Back

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Translating improved disease understanding to novel therapies in myocardial disease Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

6 More presentations in this session

Presentation thumbnail
Macrophage-derived SPP1 exacerbate myocardial injury by interacting with fibroblasts in viral myocarditis
Professor B. Han (Jinan, CN)
Abstract Slides Video
Presentation thumbnail
Clonal haematopoiesis of indeterminate potential and incident cardiomyopathy
Doctor Y. Yu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Cardiac radiation suppresses hypertrophic cardiomyopathy phenotyping in TnT R92Q HCM mice via modulating Ca2+ homeostasis
Doctor Y. Huang (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of monoclonal antibodies targeting interleukin-5 and interleukin-4/13 pathways in eosinophilic myocarditis: a single-center experience.
Doctor C. Menghi (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Amyloid staining for detection of eosinophil granules in cardiac tissue
Doctor T. Kumaki (Niigata, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Translating improved disease understanding to novel therapies in myocardial disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
thumbnail
Congress Presentation
Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM
thumbnail
Congress Presentation
Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources